SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, ...
Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in ...
For patients diagnosed with locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA), the first line of therapy often represents the most meaningful opportunity to ...
SAN FRANCISCO -- Incorporating the recently approved bispecific antibody zanidatamab (Ziihera) into first-line treatment for HER2-positive gastroesophageal cancer topped trastuzumab plus chemotherapy, ...
As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers. As the first perioperative ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved durvalumab plus fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy as ...
Imfinzi (durvalumab) is an immunotherapy medicine that helps the immune system detect and attack cancer cells. The FDA has approved a combination of Imfinzi and standard chemotherapy medicines – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results